Drug Trial Radar · NCT05579132
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
203
Planned (sponsor's estimate)
Start
Nov 1, 2022
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- MSD R&D (China) Co., Ltd.Merck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with a type of blood cancer called precursor B-cell Acute Lymphoblastic Leukemia (B-ALL) that is relapsed- the cancer has come back after treatment, or refractory - the current treatment has stopped working to slow or stop cancer growth. This study will have two parts. In the first part (dose escalation phase) the goal is to learn about the safety of a study treatment, MK-1045, and to find the best dose level of MK-1045 that is tolerated and may work to treat B-ALL. In the second part (Phase II) researchers want to learn how well MK-1045 works to treat B-ALL.
Conditions
- Acute Lymphoblastic Leukemia
Interventions
MK-1045Drug
MK-1045 is administered by IV infusion once a week (QW), 4 weeks per treatment cycle, starting with 2 cycles of induction treatment. After a 2-week treatment-free interval, responders to induction treatment receive 3 cycles of consolidation therapy, and up to 7 cycles of maintenance treatment or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, receipt of other antitumor therapy, or death, whichever occurs first. Following each consolidation and maintenance cycle, there are treatment-free intervals ranging 2-8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Phase: Number of Participants who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 24 months
- Dose Escalation Phase: Number of Participants who Discontinue Study Treatment Due to an AETime frame: Up to approximately 21 months
- Dose Escalation Phase: Number of Participants Who Experience a Dose-limiting Toxicity (DLT)Time frame: Up to 28 days
- Dose Escalation Phase: Maximum Tolerated Dose (MTD) of MK-1045Time frame: Up to approximately 21 months
- Phase II: Complete Remission (CR) RateTime frame: Up to approximately 10 weeks
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Third Military Medical University ( Site 0008)
Chongqing, Chongqing Municipality, China · Recruiting
Southern Medical University Nanfang Hospital ( Site 0004)
Guangzhou, Guangdong, China · Recruiting
The Second Hospital of Hebei Medical University ( Site 0003)
Shijiazhuang, Hebei, China · Recruiting
The First Hospital of Harbin ( Site 0005)
Harbin, Heilongjiang, China · Recruiting
Henan Cancer Hospital-hematology department ( Site 0002)
Zhengzhou, Henan, China · Recruiting
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology ( Site 0010)
Wuhan, Hubei, China · Recruiting
Tongji Hospital affiliated to Tongji Medical College of HUST ( Site 0006)
Wuhan, Hubei, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University ( Site 0007)
Xuzhou, Jiangsu, China · Active not recruiting
West China Second University Hospital, Sichuan University ( Site 0011)
Chengdu, Sichuan, China · Completed
Hematology Hospital of Chinese Academy of Medical Sciences ( Site 0001)
Tianjin, Tianjin Municipality, China · Recruiting
The Children's Hospital of Zhejiang University School of Medicine ( Site 0009)
Hangzhou, Zhejiang, China · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.